Minimally Invasive Sphincter Sparing Total Mesorectal Excision for Ultra-low Rectal Cancer After Initial Chemo-radiotherapy (MISS-TRICR). (MISS-TRICR)
Rectal Cancer
About this trial
This is an interventional treatment trial for Rectal Cancer focused on measuring low rectal cancer, minimally invasive colorectal surgery, trans-anal endoscopic microsurgery, TEM, intersphincteric resection, ISR, subtotal intersphincteric resection, total intersphincteric resection, trans-anal trans-abdominal resection, laparoscopic intersphincteric resection, anal sphincter preservation, total mesorectal excision, TME, TATA, laparoscopic total mesorectal excision, external sphincter preservation, Neoadjuvant chemo-radiotherapy for rectal cancer, fit patients for minimally invasive surgery
Eligibility Criteria
Inclusion Criteria:
- Patient with low rectal cancer below 5 cm from the anal verge
- Fit (Medically and surgically) for laparoscopy.
Exclusion Criteria:
- Patient with massive abdominal adhesions
- Unfit for laparoscopy
- Unwilling to share in the study
Sites / Locations
- Oncology centre Of Mansoura University (OCMU)
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
LISR group
TAMIS Group
Cases which undergo rectal resection with laparoscopic intersphincteric resection.
Cases with rectal cancer which undergo Transanal minimally invasive Total mesorectal excision.